Home › Compare › OASMY vs BTI

OASMY vs BTI: Dividend Comparison 2026

OASMY yields 676.00% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OASMY wins by $681598.70M in total portfolio value
10 years
OASMY
OASMY
● Live price
676.00%
Share price
$0.00
Annual div
$0.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$681598.74M
Annual income
$527,962,365,518.27
Full OASMY calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — OASMY vs BTI

📍 OASMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOASMYBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OASMY + BTI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
OASMY pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OASMY
Annual income on $10K today (after 15% tax)
$57,460.00/yr
After 10yr DRIP, annual income (after tax)
$448,768,010,690.53/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, OASMY beats the other by $448,768,008,321.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OASMY + BTI for your $10,000?

OASMY: 50%BTI: 50%
100% BTI50/50100% OASMY
Portfolio after 10yr
$340799.39M
Annual income
$263,981,184,152.45/yr
Blended yield
77.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

OASMY
No analyst data
Altman Z
-19.4
Piotroski
0/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OASMY buys
0
BTI buys
0
No recent congressional trades found for OASMY or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOASMYBTI
Forward yield676.00% ✓5.38%
Annual dividend / share$0.00$3.15 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3% ✓
Portfolio after 10y$681598.74M ✓$37.7K
Annual income after 10y$527,962,365,518.27 ✓$2,786.64
Total dividends collected$669076.90M ✓$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: OASMY vs BTI ($10,000, DRIP)

YearOASMY PortfolioOASMY Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$78,300$67,600.00$11,299$598.92+$67.0K → OASMY
2$578,461$494,680.37$12,794$703.91+$565.7K → OASMY
3$4,034,448$3,415,493.83$14,518$829.07+$4.02M → OASMY
4$26,579,641$22,262,781.88$16,513$978.64+$26.56M → OASMY
5$165,515,985$137,075,769.09$18,827$1,157.84+$165.50M → OASMY
6$974,853,824$797,751,720.50$21,518$1,373.12+$974.83M → OASMY
7$5,434,296,743$4,391,203,151.60$24,657$1,632.46+$5434.27M → OASMY
8$28,691,936,121$22,877,238,605.16$28,329$1,945.74+$28691.91M → OASMY
9$143,585,395,665$112,885,024,016.41$32,637$2,325.33+$143585.36M → OASMY
10$681,598,738,880$527,962,365,518.27$37,708$2,786.64+$681598.70M → OASMY

OASMY vs BTI: Complete Analysis 2026

OASMY — Stock

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.

Full OASMY Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this OASMY vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OASMY vs SCHDOASMY vs JEPIOASMY vs OOASMY vs KOOASMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.